Drug Profile
MK 0941
Alternative Names: MK-0941Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antihyperglycaemics
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 24 Sep 2010 Efficacy and safety data from three phase II trials in Type-2 diabetes mellitus presented at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD-2010)
- 24 Feb 2010 Merck completes two multinational phase II trials (NCT00824616 and NCT00792935) in Type-2 diabetes mellitus
- 17 Nov 2008 Phase-II clinical trials in Type-2 diabetes mellitus in European Union (PO)